{"address1": "The Mediaworks", "address2": "191 Wood Lane White City", "city": "London", "zip": "W12 7FP", "country": "United Kingdom", "phone": "44 20 3829 6230", "website": "https://www.autolus.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer and autoimmune diseases. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which is in a Phase 1 clinical trial in pediatric patients with relapsed or refractory ALL; AUTO4, a programmed T cell investigational therapy for the treatment of peripheral T-cell lymphoma targeting TRBC1 and TRBC2; AUTO6NG, a programmed T cell investigational therapy targeting GD2 in development for the treatment of neuroblastoma; and AUTO8, a product candidate to treat multiple myeloma. It focuses on developing AUTO5, a preclinical TRBC2 programmed T cell product candidate for the treatment of peripheral T-cell lymphoma. Autolus Therapeutics plc was incorporated in 2014 and is headquartered in London, the United Kingdom.", "fullTimeEmployees": 647, "companyOfficers": [{"maxAge": 1, "name": "Dr. Christian Martin Itin Ph.D.", "age": 60, "title": "CEO & Director", "yearBorn": 1964, "fiscalYear": 2024, "totalPay": 2488631, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Alex  Driggs", "age": 48, "title": "Senior VP of Legal Affairs & General Counsel and Secretary", "yearBorn": 1976, "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Christopher  Williams", "age": 44, "title": "Chief Business Officer", "yearBorn": 1980, "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Matthias  Will M.D.", "age": 51, "title": "Senior VP & Chief Development Officer", "yearBorn": 1973, "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Martin  Pule M.D., MBBS", "age": 52, "title": "Founder, Senior VP & Chief Scientific Officer", "yearBorn": 1972, "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Robert F. Dolski", "age": 53, "title": "Senior VP & CFO", "yearBorn": 1971, "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Christopher  Vann", "age": 59, "title": "Senior VP & COO", "yearBorn": 1965, "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. David  Brochu", "age": 68, "title": "Senior VP & Chief Technical Officer", "yearBorn": 1956, "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Olivia  Manser", "title": "Director of Investor Relations", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Alexander  Swan", "age": 59, "title": "Senior VP & Chief Human Resources Officer", "yearBorn": 1965, "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}], "compensationAsOfEpochDate": 1735603200, "executiveTeam": [], "maxAge": 86400, "priceHint": 4, "previousClose": 1.55, "open": 1.57, "dayLow": 1.392, "dayHigh": 1.6292, "regularMarketPreviousClose": 1.55, "regularMarketOpen": 1.57, "regularMarketDayLow": 1.392, "regularMarketDayHigh": 1.6292, "payoutRatio": 0.0, "beta": 2.064, "forwardPE": -1.9315068, "volume": 1882069, "regularMarketVolume": 1882069, "averageVolume": 1240845, "averageVolume10days": 1539250, "averageDailyVolume10Day": 1539250, "bid": 1.14, "ask": 1.8, "bidSize": 1, "askSize": 1, "marketCap": 375241856, "fiftyTwoWeekLow": 1.392, "fiftyTwoWeekHigh": 5.84, "priceToSalesTrailing12Months": 37.079235, "fiftyDayAverage": 1.9345, "twoHundredDayAverage": 3.185375, "trailingAnnualDividendRate": 0.0, "trailingAnnualDividendYield": 0.0, "currency": "USD", "tradeable": false, "enterpriseValue": 84447752, "profitMargins": 0.0, "floatShares": 137447593, "sharesOutstanding": 266128992, "sharesShort": 9131121, "sharesShortPriorMonth": 9491664, "sharesShortPreviousMonthDate": 1739491200, "dateShortInterest": 1741910400, "sharesPercentSharesOut": 0.0343, "heldPercentInsiders": 0.18087, "heldPercentInstitutions": 0.85973, "shortRatio": 7.04, "shortPercentOfFloat": 0.0452, "impliedSharesOutstanding": 266128992, "bookValue": 1.606, "priceToBook": 0.87795764, "lastFiscalYearEnd": 1735603200, "nextFiscalYearEnd": 1767139200, "mostRecentQuarter": 1735603200, "netIncomeToCommon": -220662000, "trailingEps": -0.86, "forwardEps": -0.73, "enterpriseToRevenue": 8.345, "enterpriseToEbitda": -0.362, "52WeekChange": -0.7431694, "SandP52WeekChange": 0.08089435, "quoteType": "EQUITY", "currentPrice": 1.41, "targetHighPrice": 14.0, "targetLowPrice": 6.0, "targetMeanPrice": 10.1, "targetMedianPrice": 10.0, "recommendationMean": 1.2, "recommendationKey": "strong_buy", "numberOfAnalystOpinions": 9, "totalCash": 588022976, "totalCashPerShare": 2.21, "ebitda": -233072992, "totalDebt": 297228992, "quickRatio": 10.475, "currentRatio": 10.881, "totalRevenue": 10120000, "debtToEquity": 69.556, "revenuePerShare": 0.04, "returnOnAssets": -0.2599, "returnOnEquity": -0.81908995, "grossProfits": -130900000, "freeCashflow": -187041872, "operatingCashflow": -206271008, "grossMargins": 0.0, "ebitdaMargins": 0.0, "operatingMargins": -2616.0, "financialCurrency": "USD", "symbol": "AUTL", "language": "en-US", "region": "US", "typeDisp": "Equity", "quoteSourceName": "Nasdaq Real Time Price", "triggerable": true, "customPriceAlertConfidence": "HIGH", "regularMarketChangePercent": -9.032258, "regularMarketPrice": 1.41, "marketState": "PRE", "shortName": "Autolus Therapeutics plc", "longName": "Autolus Therapeutics plc", "corporateActions": [], "preMarketTime": 1743593723, "regularMarketTime": 1743537601, "exchange": "NMS", "messageBoardId": "finmb_562879769", "exchangeTimezoneName": "America/New_York", "exchangeTimezoneShortName": "EDT", "gmtOffSetMilliseconds": -14400000, "market": "us_market", "esgPopulated": false, "preMarketChange": 0.0, "preMarketChangePercent": 0.0, "preMarketPrice": 1.41, "regularMarketChange": -0.13999999, "regularMarketDayRange": "1.392 - 1.6292", "fullExchangeName": "NasdaqGS", "averageDailyVolume3Month": 1240845, "fiftyTwoWeekLowChange": 0.018000007, "fiftyTwoWeekLowChangePercent": 0.01293104, "fiftyTwoWeekRange": "1.392 - 5.84", "fiftyTwoWeekHighChange": -4.4300003, "fiftyTwoWeekHighChangePercent": -0.7585617, "fiftyTwoWeekChangePercent": -74.31694, "earningsTimestamp": 1742468401, "earningsTimestampStart": 1747485000, "earningsTimestampEnd": 1748694600, "earningsCallTimestampStart": 1742473800, "earningsCallTimestampEnd": 1742473800, "isEarningsDateEstimate": true, "epsTrailingTwelveMonths": -0.86, "epsForward": -0.73, "epsCurrentYear": -0.91393, "priceEpsCurrentYear": -1.5427877, "fiftyDayAverageChange": -0.5245, "fiftyDayAverageChangePercent": -0.2711295, "twoHundredDayAverageChange": -1.775375, "twoHundredDayAverageChangePercent": -0.55735195, "sourceInterval": 15, "exchangeDataDelayedBy": 0, "averageAnalystRating": "1.2 - Strong Buy", "cryptoTradeable": false, "hasPrePostMarketData": true, "firstTradeDateMilliseconds": 1529674200000, "displayName": "Autolus Therapeutics", "trailingPegRatio": null}